— Know what they know.
Not Investment Advice
Also trades as: 0QZM.L (LSE) · $vol 0M · AXP.DE (XETRA) · $vol 0M

ALXN NASDAQ

Alexion Pharmaceuticals, Inc.
1W: -1.9% 1M: +1.0% 3M: +9.6% 1Y: +66.6% 3Y: +34.5% 5Y: +45.5%
$182.50
Last traded 2021-07-20 — delisted
NASDAQ · Healthcare · Biotechnology

Cash Flow Trends

Operating Cash Flow
$3.0B +44.0% ▲
5Y CAGR: +34.8%
Capital Expenditures
$107M +37.5% ▲
5Y CAGR: -17.9%
Free Cash Flow
$2.9B +51.3% ▲
5Y CAGR: +49.4%
Dividends Paid
$0 +0.0% ▲
Buybacks
$511M -22.8% ▼
Net Change in Cash
$311M -77.1% ▼

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2016FY2017FY2018FY2019FY2020
— Operating Activities —
Net Income$399M$443M$78M$2.4B$603M
Depreciation & Amort.$396M$497M$405M$377M$329M
Stock-Based Comp.$192M$243M$203M$237M$281M
Change in Working Capital-$136M-$170M-$434M-$276M-$34M
Other Non-Cash Items$131M$149M$141M-$201M$2.1B
Operating Cash Flow$1.1B$1.1B$426M$2.1B$3.0B
— Investing Activities —
Capital Expenditures-$333M-$357M-$213M-$171M-$107M
Acquisitions (Net)$0$0$0$115M-$2.1B
Investment Purchases-$675M-$1.7B-$805M-$171M-$77M
Investment Sales$722M$1.1B$1.5B$237M$196M
Other Investing-$1M$100K$3M-$100K$0
Investing Cash Flow-$287M-$918M$470M$10M-$2.1B
— Financing Activities —
Net Debt Issuance$0$0$0$0$0
Stock Repurchased-$430M-$464M-$85M-$416M-$511M
Dividends Paid$0$0$0$0$0
Other Financing-$836M-$597M-$102M-$739M-$612M
Financing Cash Flow-$836M-$597M-$102M-$739M-$612M
Net Change in Cash-$44M-$382M$783M$1.4B$311M
Cash End of Period$966M$584M$1.4B$2.7B$3.0B
Free Cash Flow$753M$758M$213M$1.9B$2.9B

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms